NIH awards Duke University $5.89M for HIV Env Trimer Liposome/LNP mRNA research

Contract Overview

Contract Amount: $5,885,384 ($5.9M)

Contractor: Duke University

Awarding Agency: Department of Health and Human Services

Start Date: 2024-08-31

End Date: 2028-08-27

Contract Duration: 1,457 days

Daily Burn Rate: $4.0K/day

Competition Type: FULL AND OPEN COMPETITION

Number of Offers Received: 2

Pricing Type: COST NO FEE

Sector: R&D

Official Description: FEASIBILITY FOR DEVELOPMENT OF A LIPOSOME/LNP DISPLAYING AN HIV ENV TRIMER PROTEIN AND CONTAINING/INCORPORATING AN MRNA

Place of Performance

Location: DURHAM, DURHAM County, NORTH CAROLINA, 27708

State: North Carolina Government Spending

Plain-Language Summary

Department of Health and Human Services obligated $5.9 million to DUKE UNIVERSITY for work described as: FEASIBILITY FOR DEVELOPMENT OF A LIPOSOME/LNP DISPLAYING AN HIV ENV TRIMER PROTEIN AND CONTAINING/INCORPORATING AN MRNA Key points: 1. Contract focuses on novel delivery systems for HIV vaccine development. 2. Research aims to improve mRNA vaccine efficacy and stability. 3. Potential for significant public health impact in HIV prevention. 4. Funding supports early-stage R&D with inherent scientific uncertainty. 5. Duke University has a strong track record in biomedical research. 6. Contract type is a delivery order under a larger IDIQ, indicating ongoing program needs.

Value Assessment

Rating: good

The contract value of $5.89 million for a 4-year research project appears reasonable given the specialized nature of the work and the reputation of Duke University. Benchmarking against similar NIH-funded R&D contracts for vaccine delivery systems suggests this is within expected parameters. The 'Cost No Fee' (NC) contract type indicates that the government will reimburse allowable costs up to the agreed-upon amount, which is standard for this type of research where outcomes are uncertain.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

The contract was awarded under full and open competition, suggesting multiple qualified entities had the opportunity to bid. While the specific number of bidders is not provided, this procurement method generally fosters competitive pricing and encourages innovation. The use of a delivery order under an existing contract vehicle implies that the initial competition for the broader contract vehicle was robust.

Taxpayer Impact: Full and open competition is beneficial for taxpayers as it increases the likelihood of obtaining the best value through a competitive process, driving down costs and improving the quality of research.

Public Impact

The primary beneficiaries are public health organizations and individuals at risk of HIV infection, through the potential development of a more effective HIV vaccine. The services delivered involve cutting-edge research in molecular biology, immunology, and pharmaceutical sciences. The geographic impact is national, with potential global implications if a successful vaccine is developed. Workforce implications include support for researchers, technicians, and students at Duke University, fostering expertise in vaccine technology.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Scientific research inherently carries risks of not achieving desired outcomes within the projected timeline or budget.
The novelty of the delivery system may present unforeseen technical challenges during development.

Positive Signals

Duke University's established expertise in virology and vaccine development is a significant positive signal.
The focus on mRNA technology aligns with recent advancements in vaccine platforms.
The 'Cost No Fee' structure, while common, implies a strong partnership and shared commitment to the research goals.

Sector Analysis

This contract falls within the Biotechnology and Pharmaceutical Research and Development sector, specifically focusing on novel vaccine delivery systems. The market for vaccine development is highly competitive and innovation-driven, with significant government investment. Comparable spending benchmarks would involve other NIH grants and contracts awarded for early-stage vaccine research, which can range from hundreds of thousands to tens of millions of dollars depending on the scope and phase.

Small Business Impact

There is no indication of a small business set-aside for this contract, which is typical for large-scale, specialized research grants awarded to major academic institutions. Subcontracting opportunities for small businesses are unlikely to be a primary focus, though specialized reagents or services might be procured from small business vendors.

Oversight & Accountability

Oversight is primarily managed by the National Institutes of Health (NIH), which will monitor the progress and expenditures of the grant. Accountability measures are built into the research reporting requirements, with regular progress reports and final reports expected. Transparency is maintained through public databases of federal awards. Inspector General jurisdiction would apply in cases of fraud, waste, or abuse.

Related Government Programs

NIH Research and Development Contracts
HIV Vaccine Research Programs
mRNA Vaccine Technology Development
Biotechnology Research Grants

Risk Flags

Scientific uncertainty inherent in R&D
Technical feasibility of novel delivery system
Potential for long development timelines

Frequently Asked Questions

What is this federal contract paying for?

Department of Health and Human Services awarded $5.9 million to DUKE UNIVERSITY. FEASIBILITY FOR DEVELOPMENT OF A LIPOSOME/LNP DISPLAYING AN HIV ENV TRIMER PROTEIN AND CONTAINING/INCORPORATING AN MRNA

Who is the contractor on this award?

The obligated recipient is DUKE UNIVERSITY.

Which agency awarded this contract?

Awarding agency: Department of Health and Human Services (National Institutes of Health).

What is the total obligated amount?

The obligated amount is $5.9 million.

What is the period of performance?

Start: 2024-08-31. End: 2028-08-27.

What is Duke University's track record with NIH-funded research, particularly in vaccine development?

Duke University has a long and distinguished history of receiving significant funding from the National Institutes of Health (NIH) for a wide array of research projects, including those in vaccine development, infectious diseases, and immunology. Their research portfolio often includes complex, multi-year projects requiring substantial expertise and infrastructure. Specific to vaccine development, Duke has been involved in research related to various pathogens, leveraging advanced technologies. Their consistent success in securing NIH grants underscores their strong scientific reputation, research capabilities, and ability to meet the rigorous requirements set forth by federal funding agencies. This background suggests a high likelihood of successful project execution for the current HIV Env Trimer research.

How does the value of this contract compare to similar R&D efforts in vaccine delivery systems?

The $5.89 million award to Duke University for developing a liposome/LNP displaying an HIV Env Trimer protein and incorporating mRNA is within the typical range for early-stage, high-risk, high-reward research in vaccine technology. NIH funding for such projects can vary widely, but contracts in the multi-million dollar range over several years are common for complex biological research. For instance, other NIH-funded projects exploring novel delivery mechanisms for mRNA vaccines or targeting challenging pathogens like HIV have received similar levels of funding. The 'Cost No Fee' (NC) designation means the government reimburses actual costs incurred, up to the award ceiling, which is standard for research where precise costs are hard to predict. This value appears appropriate for the scope and duration of the proposed work.

What are the primary scientific and technical risks associated with this contract?

The primary scientific and technical risks associated with this contract revolve around the inherent uncertainties of cutting-edge research. Developing a novel liposome/LNP delivery system that effectively displays an HIV Env Trimer protein and incorporates mRNA presents significant formulation and stability challenges. Ensuring the correct structure and immunogenicity of the Env Trimer within the lipid nanoparticle is critical and may prove difficult. Furthermore, the efficient and targeted delivery of mRNA to relevant immune cells, and its subsequent translation into protective antigens, requires overcoming biological barriers. There's also a risk that the developed system may not elicit the desired immune response or may have unforeseen toxicity issues. The success hinges on overcoming multiple complex biological and chemical engineering hurdles.

What is the potential impact of this research on HIV prevention strategies?

This research has the potential to significantly advance HIV prevention strategies by contributing to the development of a more effective HIV vaccine. Current HIV vaccine candidates have faced numerous challenges, partly due to the virus's complexity and ability to evade the immune system. By focusing on a novel delivery system (liposome/LNP) that can present key viral components (HIV Env Trimer) and utilize mRNA technology, this project aims to overcome some of these limitations. If successful, this approach could lead to a vaccine that elicits a stronger and more durable immune response against HIV, potentially offering a new tool in the global fight against the epidemic. It represents an investment in innovative science that could yield breakthrough prevention methods.

How does this contract align with broader NIH and federal priorities for infectious disease research?

This contract strongly aligns with the broader priorities of the National Institutes of Health (NIH) and the federal government concerning infectious disease research, particularly HIV/AIDS. The NIH, through various institutes like NIAID (National Institute of Allergy and Infectious Diseases), consistently funds research aimed at understanding, preventing, and treating infectious diseases. Developing effective vaccines remains a cornerstone of these efforts. The focus on innovative delivery platforms like liposomes/LNPs and mRNA technology reflects the NIH's commitment to supporting cutting-edge scientific approaches that have shown promise in other areas (e.g., COVID-19 vaccines). By investing in this research, the federal government is prioritizing the development of next-generation biomedical countermeasures against persistent public health threats like HIV.

Industry Classification

NAICS: Professional, Scientific, and Technical Services › Scientific Research and Development Services › Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Product/Service Code: RESEARCH AND DEVELOPMENT › N – Health R&D Services

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: SUBJECT TO MULTIPLE AWARD FAIR OPPORTUNITY

Solicitation ID: 75N93024R00035

Offers Received: 2

Pricing Type: COST NO FEE (S)

Evaluated Preference: NONE

Contractor Details

Address: 2200 W MAIN ST STE 710, DURHAM, NC, 27708

Business Categories: Category Business, Corporate Entity Tax Exempt, Educational Institution, Higher Education, Nonprofit Organization, Not Designated a Small Business, Higher Education (Private)

Financial Breakdown

Contract Ceiling: $5,885,384

Exercised Options: $5,885,384

Current Obligation: $5,885,384

Actual Outlays: $388,059

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES PROCEDURES NOT USED

Cost or Pricing Data: NO

Parent Contract

Parent Award PIID: 75N93022D00003

IDV Type: IDC

Timeline